WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs

Raccontata dafiercepharma.commorningstar.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
morningstar.comStai leggendo1 mesi fa

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes…

50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs

originale
fiercepharma.com1 mesi fa

Niowave kicks off construction of $75M radiopharmaceutical isotope plant in Michigan

After striking radiopharmaceutical supply deals with pharma giants Novartis and AstraZeneca within the last six months, Niowave is taking steps to meet growing demand for the alpha-emitting is | Niowave has broken…

Leggi questa versione →

Timeline cronologica

  1. martedì 26 maggio 2026·fiercepharma.com

    Niowave kicks off construction of $75M radiopharmaceutical isotope plant in Michigan

    After striking radiopharmaceutical supply deals with pharma giants Novartis and AstraZeneca within the last six months, Niowave is taking steps to meet growing demand for…

  2. mercoledì 27 maggio 2026·morningstar.com

    Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by…

    50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs

originale
  • giovedì 28 maggio 2026·morningstar.com

    Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer

    Experienced oncology R&D leader appointed to support Aptevo's expanding oncology pipeline and new radiopharmaceutical development strategy SEATTLE, WA / ACCESS Newswire / May 28,…